Table 1 The predictive value of PDXs for clinical outcome
From: Patient-derived xenografts: a relevant preclinical model for drug development
Tumour histotype | Authors | Modela | Treatment/ molecular alterations | Corrispondence with patientsb |
|---|---|---|---|---|
Breast cancer | Marangoni et al. (ref. 8) | PDOXs (7) | Docetaxel, 5-Fluorouracil, Trastuzumab | 5/7 |
Zhang et al. (ref. 19) | PDOXs (10) | Docetaxel, Doxorubicin, Trastuzumab + Lapatinib | 10/10 | |
Colorectal cancer | Bertotti et al. (ref. 17) | PDXs (85) | Cetuximab, Panitumumab | 85/85 |
Ovarian cancer | Ricci et al. (ref. 9) | PDXs (11) | Cisplatin | 9/11 |
Topp et al. (ref. 6) | PDXs (10) | Cisplatin | 10/10 | |
Small cell lung cancer | Anderson et al. (ref. 23) | PDXs (8) | Cisplatin, Etoposide | 7/8 |
Colorectal cancer | Nunes et al. (ref. 7) | PDXs (52) | WT KRAS (8/52) | 8/8 responded to Cetuximab |
Bertotti et al. (ref. 17) | PDXs (85) | KRAS mutated (18/85) | 18/18 not responded to Cetuximab | |
Non-small cell lung cancer | Zhang et al. (ref.12) | PDXs (10) | EGFR mutated (1/10) | 1/10 responded to Gefitinib |